8-Deoxy-11,13-dihydroxygrosheimin | 83551-03-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 8-Deoxy-11,13-dihydroxygrosheimin
• 英文别名: 3-hydroxy-3-(hydroxymethyl)-9-methyl-6-methylidene-3a,4,5,6a,7,9,9a,9b-octahydroazuleno[4,5-b]furan-2,8-dione
• CAS: 83551-03-5
• 化学式: C₁₅H₂₀O₅
• 分子量: 280.32
• InChiKey: XJUFXNXZZRHROZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  83.8
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Use of tricyclic sesquiterpene lactones in the treatment of obesity and related diseases and non-therapeutic treatable conditions
  申请人：InterMed Discovery GmbH

  公开号：EP2345646A1

  公开（公告）日：2011-07-20

  A compound of the formula I, wherein the symbols are as defined in the remaining specification, or a mixture of two or more compounds of the formula I, for use as active ingredient in the therapeutic - including prophylactic - treatment of a warm-blooded animal for the regulation of body weight (preferred) and/or fat loss (preferred) and/or for the management of obesity and/or for decreasing blood cholesterol; where the compound(s) of the formula I may be present in free form, in the form of a pharmaceutically and/or nutraceutically acceptable salt, in the form of tautomers, in the form of esters and/or in the form of solvates, as well as related invention embodiments.

  式 I 的化合物、 其中符号如其余说明书中所定义，或两种或两种以上式 I 化合物的混合物，作为活性成分用于温血动物的治疗（包括预防性治疗），以调节体重（优选）和/或减脂（优选）和/或控制肥胖和/或降低血液中的胆固醇；式 I 的化合物可以游离形式、药学上和/或营养学上可接受的盐的形式、同分异构体的形式、酯的形式和/或溶解物的形式以及相关的发明实施方案的形式存在。
• USE OF TRICYCLIC SESQUITERPENE LACTONES IN THE TREATMENT OF OBESITY AND RELATED DISEASES AND NON-THERAPEUTIC TREATABLE CONDITIONS
  申请人：Neem Biotech Ltd.

  公开号：EP3260449A1

  公开（公告）日：2017-12-27

  A compound of the formula I, wherein the symbols are as defined in the remaining specification, or a mixture of two or more compounds of the formula I, for use as active ingredient in the therapeutic - including prophylactic - treatment of a warm-blooded animal for the regulation of body weight (preferred) and/or fat loss (preferred) and/or for the management of obesity and/or for improving the total cholesterol HDL/LDL ratio; where the compound(s) of the formula I may be present in free form, in the form of a pharmaceutically and/or nutraceutically acceptable salt, in the form of tautomers, in the form of esters and/or in the form of solvates, as well as related invention embodiments.

  式 I 的化合物、 其中符号如其余说明书中所定义，或两种或两种以上式 I 化合物的混合物，作为活性成分用于温血动物的治疗--包括预防--调节体重（优选）和/或减脂（优选）和/或控制肥胖和/或改善总胆固醇 HDL/LDL 比率；其中式 I 的化合物可以游离形式、药学上和/或营养学上可接受的盐的形式、同分异构体的形式、酯的形式和/或溶解物的形式以及相关的发明实施方案的形式存在。
• Tricyclic sesquiterpene lactones for used in the treatment of obesity and related diseases and non-therapeutic treatable conditions
  申请人：Neem Biotech Ltd.

  公开号：EP2523946B1

  公开（公告）日：2017-09-20
• [EN] USE OF TRICYCLIC SESQUITERPENE LACTONES IN THE TREATMENT OF OBESITY AND RELATED DISEASES AND NON-THERAPEUTIC TREATABLE CONDITIONS<br/>[FR] UTILISATION DE SESQUITERPÈNE-LACTONES TRICYCLIQUES DANS LE TRAITEMENT DE L'OBÉSITÉ, DE MALADIES ASSOCIÉES ET DE TROUBLES NON THÉRAPEUTIQUEMENT TRAITABLES
  申请人：INTERMED DISCOVERY GMBH

  公开号：WO2011085979A1

  公开（公告）日：2011-07-21

  A compound of the formula I, wherein the symbols are as defined in the remaining specification, or a mixture of two or more compounds of the formula I, for use as active ingredient in the therapeutic - including prophylactic - treatment of a warm-blooded animal for the regulation of body weight (preferred) and/or fat loss (preferred) and/or for the management of obesity and/or for improving the total cholesterol HDL/LDL ratio; where the compound(s) of the formula I may be present in free form, in the form of a pharmaceutically and/or nutraceutically acceptable salt, in the form of tautomers, in the form of esters and/or in the form of solvates, as well as related invention embodiments.